|
Real-time Estimate
Cboe BZX
23:11:36 16/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 263.09 USD | +0.02% |
|
+4.56% | +14.82% |
| 09-15 | AbbVie Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 10:00 AM | |
| 09-15 | Testosterone scripts for women rise, along with denials and delays | RE |
| Market Cap | 465B 403B 381B 346B 648B 44,591B 652B 4,545B 1,756B 22,617B 1,746B 1,707B 72,091B | P/E 2026 * |
33.3x | P/E 2027 * | 24.8x |
|---|---|---|---|---|---|
| Enterprise Value | 526B 456B 431B 391B 734B 50,500B 738B 5,147B 1,989B 25,614B 1,977B 1,934B 81,644B | EV / Sales 2026 * |
7.79x | EV / Sales 2027 * | 7.05x |
| Free-Float |
95.71% | Yield 2026 * |
2.61% | Yield 2027 * | 2.74% |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| ABBV | Delayed | |
CBOE
| ABBV | Real-time | |
|
Tradegate
| 4AB | Real-time | |
|
London S.E.
| 0QCV | Delayed | |
|
Xetra
| 4AB | Delayed | |
|
Boerse Muenchen
| 4AB | Real-time | |
|
Mexican S.E.
| ABBV * | End-of-day quote | |
|
Börse Stuttgart
| 4AB | Delayed | |
|
Deutsche Boerse AG
| 4AB | Delayed | |
|
Swiss Exchange
| ABBV | Delayed | |
|
Wiener Boerse
| ABBV | End-of-day quote | |
|
Borsa Italiana
| 1ABBV | End-of-day quote | |
|
CBOE
| 0QCV | Real-time | |
|
CBOE
| Real-time | ||
|
Santiago S.E.
| ABBV | End-of-day quote | |
|
Santiago S.E.
| ABBVCL | End-of-day quote | |
|
Swiss Exchange
| ABBV | Delayed |
Last Transcript: AbbVie Inc.
| 1 day | +0.02% | ||
| 1 week | +4.56% | ||
| Current month | +2.31% | ||
| 1 month | +4.80% | ||
| 3 months | +17.93% | ||
| 6 months | +18.47% | ||
| Current year | +14.82% |
| 1 week | 249.74 |  | 264.81 |
| 1 month | 246.77 | | 266.96 |
| Current year | 190.75 | | 267.47 |
| 1 year | 190.75 | | 267.47 |
| 3 years | 135.85 | | 267.47 |
| 5 years | 105.56 | | 267.47 |
| 10 years | 55.06 | | 267.47 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Michael
CEO | Chief Executive Officer | 55 | 01/07/2024 |
Scott Reents
DFI | Director of Finance/CFO | 59 | 23/06/2022 |
Linda Ray
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 65 | 01/01/2013 |
William Burnside
BRD | Director/Board Member | 74 | 01/01/2013 |
Ed Rapp
BRD | Director/Board Member | 69 | 01/01/2013 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/14/26 A | Exercice | Executive/Senior Manager | 98,130 | 0.0056% | ||
| 6/30/26 A | Free | Director | 62 | 0.0000% | ||
| 6/30/26 A | Free | Director | 134 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.02% | +4.56% | +21.31% | +70.42% | 465B | |
| -0.45% | +1.14% | +48.69% | +99.04% | 1,013B | |
| +0.65% | +0.12% | +51.54% | +64.58% | 644B | |
| +0.53% | +3.42% | +39.21% | +38.70% | 352B | |
| +0.39% | +2.22% | +17.02% | +23.87% | 264B | |
| +0.17% | +4.17% | +6.96% | +13.12% | 253B | |
| +0.39% | -4.02% | +37.51% | +42.71% | 203B | |
| -1.20% | -6.64% | -23.23% | -59.10% | 188B | |
| +0.96% | +1.26% | +33.03% | +95.03% | 181B | |
| -0.44% | -1.17% | +14.87% | -18.39% | 157B | |
| Average | +0.07% | -0.92% | +24.69% | +37.00% | 372.07B | |
| Weighted average by Cap. | +0.05% | +0.05% | +33.33% | +56.37% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 67.59B 58.57B 55.36B 50.26B 94.2B 6,484B 94.76B 661B 255B 3,289B 254B 248B 10,483B | 73.49B 63.69B 60.19B 54.65B 102B 7,050B 103B 719B 278B 3,576B 276B 270B 11,398B |
| Net income | 14.08B 12.2B 11.53B 10.47B 19.62B 1,351B 19.74B 138B 53.2B 685B 52.89B 51.71B 2,184B | 19.09B 16.54B 15.63B 14.19B 26.6B 1,831B 26.76B 187B 72.12B 929B 71.7B 70.11B 2,960B |
| Net Debt | 61.59B 53.38B 50.45B 45.8B 85.84B 5,909B 86.35B 602B 233B 2,997B 231B 226B 9,553B | 53.09B 46.01B 43.49B 39.48B 73.99B 5,093B 74.43B 519B 201B 2,583B 199B 195B 8,234B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/09/26 | $262.64 | -0.15% | 1,981,896 |
| 15/09/26 | $263.04 | +0.49% | 5,120,219 |
| 14/09/26 | $261.77 | +1.81% | 4,512,420 |
| 11/09/26 | $257.12 | +0.83% | 4,308,856 |
| 10/09/26 | $255.00 | +1.63% | 4,397,653 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ABBV Stock
Select your edition
All financial news and data tailored to specific country editions
